

© 2013 Alberta Health Services. This material is provided on an "as is", "where is" basis. Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use.

RS - 33

Long Term Care Formulary

Long renn Gare i Onnalary			I CO	00
SECTION	SUBJECT	PAGE		
RESTRICTED USE	calcitonin (Calcimar®) 200 IU/mL injection	1 of 1		
		YY	ММ	DD
	Original	01	06	28
	Revised	03	08	28
	Revised	06	02	23
	Revised	14	01	23

Note: January 2014 update removes calcitonin nasal spray from restriction (removed from Canadian market October 2013)

Calcitonin 200 UI/mL injection is approved for use under the following conditions:

PROTOCOL 1 – Paget's Disease

• Treatment of Paget's disease for patients who do not respond to alternative treatments or for whom alternatives are not suitable; duration of treatment should not exceed <u>3 months</u>. In exceptional circumstances (e.g. in patients with impending pathological fracture) treatment duration may be extended up to a maximum of 6 months.

PROTOCOL 2 – Bone Pain Secondary to Recent Osteoporotic Fracture

Prevention of bone loss and treatment of bone pain from sudden immobilization associated with
recent osteoporotic fractures. Treatment duration should be limited to <u>2 weeks</u> and not to
exceed <u>4 weeks</u> in any case.

PROTOCOL 3 – Hypercalcemic Emergencies

• Early treatment of hypercalcemic emergencies and the treatment of hypercalcemia associated with malignancy

All other uses and indications for calcitonin injectable will required application via the non-formulary/special authorization process.